1. Home
  2. CTSO vs NEUP Comparison

CTSO vs NEUP Comparison

Compare CTSO & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.46

Market Cap

26.5M

Sector

Health Care

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.17

Market Cap

23.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTSO
NEUP
Founded
1997
1996
Country
United States
United States
Employees
N/A
8
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.5M
23.1M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
CTSO
NEUP
Price
$0.46
$4.17
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$5.38
$21.00
AVG Volume (30 Days)
209.1K
57.7K
Earning Date
05-01-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
65.79
N/A
EPS
N/A
N/A
Revenue
$22,503,908.00
N/A
Revenue This Year
$10.34
N/A
Revenue Next Year
$22.41
N/A
P/E Ratio
N/A
N/A
Revenue Growth
48.53
N/A
52 Week Low
$0.37
$3.65
52 Week High
$1.39
$21.31

Technical Indicators

Market Signals
Indicator
CTSO
NEUP
Relative Strength Index (RSI) 45.56 34.47
Support Level $0.37 $3.91
Resistance Level $0.72 $4.56
Average True Range (ATR) 0.06 0.30
MACD 0.01 -0.07
Stochastic Oscillator 35.57 22.22

Price Performance

Historical Comparison
CTSO
NEUP

About CTSO Cytosorbents Corporation

CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: